Protara Therapeutics Inc (TARA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $155.77M
Last updated: Nov 17, 2026 at 11:06 AM ET
Protara Therapeutics Inc (TARA) Stock Forecast
Analysts expect Protara Therapeutics (TARA) to earn -$1.36 per share in the fiscal year ending Dec 31, 2026. Of 8 analysts, 8 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 5 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 1.75, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 25.0% |
| Buy | 6 | 75.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$1.36
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.68
- EPS consensus, revenue $1.17M
- Next report
- Mar 8, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.36 | -$1.38 to -$1.30 | 4 | N/A | N/A | 6 |
| Dec 31, 2027 | -$1.68 | -$2.25 to -$1.13 | 7 | $1.17M | N/A | 6 |
Quarterly Estimates
The EPS consensus falls from -$0.37 for the quarter ending Dec 31, 2026 to -$0.44 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.37 | -$0.37 to -$0.36 | 9 |
| Mar 31, 2027 | -$0.44 | -$0.46 to -$0.42 | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 9 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 5 |
| Fiscal year ending Dec 31, 2027 | 1 | 3 |
| Quarter ending Mar 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.39.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.36 | -$1.39 | -$1.39 | -$1.39 | -$1.39 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.68 | -$1.69 | -$1.69 | -$1.69 | -$1.67 | N/A |
| Quarter ending Mar 31, 2027 | -$0.44 | -$0.43 | -$0.43 | -$0.43 | -$0.45 | N/A |
Frequently Asked Questions About TARA
What is the TARA stock forecast?
Consensus analyst estimates put Protara Therapeutics's EPS at -$1.36 for the fiscal year ending Dec 31, 2026. The consensus rating from 8 analysts is Buy.
How do analysts rate TARA stock?
Of 8 analysts covering Protara Therapeutics, 2 rate it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TARA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.36, with estimates from -$1.38 to -$1.30 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.68, with estimates from -$2.25 to -$1.13 from 7 analysts.
What revenue do analysts expect from Protara Therapeutics next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.17M.
How many analysts cover TARA?
8 analysts rate Protara Therapeutics stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TARA pages: Overview, Earnings, Forecast, Financials, Competitors